title: Co-existence of cutaneous leishmaniasis with pleural effusion: a case report from Iran.
abstract: Herein, a 12-year-old Afghan boy with chronic cutaneous leishmaniasis on the face and verrucous lesions on the body and pleural effusion suspected of having co-existent tuberculosis has been presented. The cutaneous lesions were appeared for five years before his admission. Leishman-Donovan bodies were seen in H&E (Hematoxylin and eosin) slide of skin lesion specimens. The pathogenic species was proved to be Leishmania tropica using Polymerase Chain Reaction (PCR) method. Purified Protein Derivative (PPD) and Leishmanin Skin Test (LST) were strongly positive. The patient was treated with systemic and intralesional meglumine antimoniate (Glucantime) for cutaneous leishmaniasis and then with anti-tuberculosis drugs for pleural effusion. Afterwards, pleural effusion was disappeared and cutaneous leishmaniasis cured.
authors.affiliation: Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran AND Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran. mortazavi_ho@yahoo.com.
authors.forename: Hossein
authors.initials: H
authors.lastname: Mortazavi
authors.affiliation: Department of Infectious Diseases, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran. tara_soori@yahoo.com.
authors.forename: Tahereh
authors.initials: T
authors.lastname: Soori
authors.affiliation: Skin and Leprosy Research Center, Tehran University of Medical Sciences, Tehran, Iran. Khamesipour_ali@yahoo.com.
authors.forename: Ali
authors.initials: A
authors.lastname: Khamesipour
authors.affiliation: Skin and Leprosy Research Center, Tehran University of Medical Sciences, Tehran, Iran. tsoori@razi.tums.ac.ir.
authors.forename: Alireza
authors.initials: A
authors.lastname: Khatami
authors.affiliation: Skin and Leprosy Research Center, Tehran University of Medical Sciences, Tehran, Iran. tsoori@razi.tums.ac.ir.
authors.forename: Amir
authors.initials: A
authors.lastname: Vasheghani-Farahani
mesh_terms: D000981:Antiprotozoal Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D002648:Child; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D010996:Pleural Effusion / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000382:microbiology*; D016133:Polymerase Chain Reaction; D014057:Tomography, X-Ray Computed; D014397:Tuberculosis, Pulmonary / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000382:microbiology*
chemical_list: D000981:Antiprotozoal Agents; D000995:Antitubercular Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate